Keywordsantibiobic; microbiota; butyrate; histone modifications; host defense peptides; LL-37; innate immunity; impaired immune responses; Clostridium difficile; antibiotic-associated diarrhea; Clostridium difficile; antimicrobial; antimicrobial peptide; AMP; resistance; antimicrobial peptide; microbicide; cryptdin; facultative; microbiota; ileum; anti-biofilm; immunomodulation; peptides; antibiotic-resistance; cystic fibrosis; antimicrobial; CXCL10; IP-10; dermal microorganisms; oral microorganisms; SMAP28; vibrio; lipopolysaccharide; outer membrane vesicle; membrane transporter; innate immunity; defensin; cathelicidin; bactericidal/permeability-increasing protein; antimicrobial peptides; tritrpticin; membrane permeabilization; tryptophan; fluorescence spectroscopy; NMR spectroscopy; antimicrobial peptides; host defense peptides; defensins; antibiotics; mode of action; antimicrobial peptides; pathogenesis; bacteria; microenvironment; therapeutics; HIV-1; cationic; antimicrobial; peptide; protein; cervix; vagina; mucosa; protegrin-1 (PG-1); Toll-like receptor (TLR) ligands; cytokines; macrophage; innate immunity; antimicrobial peptide; AMP; CAMP; antibiotic resistance; Gram-negative; chromatin remodeling; histone deacetylase inhibitors; antimicrobial peptides; bacterial infections; anti-infectives; cystic fibrosis; Neutrophil; NETs; Host defense peptides; Asian frog; Multi-drug resistance; Anti-microbial peptides
